Matt Miksic
Stock Analyst at Barclays
(3.73)
# 687
Out of 5,152 analysts
334
Total ratings
55.56%
Success rate
5.34%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LIVN LivaNova | Maintains: Equal-Weight | $67 → $73 | $62.87 | +16.11% | 10 | Feb 27, 2026 | |
| ALC Alcon | Maintains: Equal-Weight | $86 → $90 | $80.67 | +11.57% | 11 | Feb 26, 2026 | |
| GMED Globus Medical | Maintains: Overweight | $118 → $123 | $86.17 | +42.74% | 17 | Feb 25, 2026 | |
| BLCO Bausch + Lomb | Maintains: Equal-Weight | $17 → $20 | $17.08 | +17.10% | 7 | Feb 19, 2026 | |
| MDT Medtronic | Maintains: Overweight | $116 → $118 | $90.58 | +30.27% | 25 | Feb 18, 2026 | |
| DXCM DexCom | Maintains: Underweight | $71 → $72 | $68.18 | +5.60% | 10 | Feb 13, 2026 | |
| BAX Baxter International | Maintains: Overweight | $30 → $25 | $17.78 | +40.61% | 24 | Feb 13, 2026 | |
| ZBH Zimmer Biomet Holdings | Maintains: Underweight | $104 → $100 | $92.56 | +8.04% | 10 | Feb 12, 2026 | |
| BDX Becton, Dickinson and Company | Reinstates: Overweight | $202 | $165.46 | +22.08% | 2 | Feb 11, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Equal-Weight | $86 → $87 | $74.50 | +16.78% | 2 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $136 → $124 | $71.63 | +73.11% | 20 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $169 → $142 | $109.53 | +29.64% | 32 | Feb 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $98 | $77.10 | +27.11% | 2 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $686 → $712 | $484.67 | +46.90% | 9 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $103 → $104 | $81.21 | +28.06% | 32 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $316 → $274 | $235.92 | +16.14% | 12 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $12 | $4.46 | +169.06% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $27 | $12.20 | +121.40% | 5 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $197 → $217 | $236.13 | -8.10% | 15 | Dec 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $55 | $21.39 | +157.13% | 8 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1.5 → $31 | $6.02 | +414.95% | 2 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $443 → $453 | $362.49 | +24.97% | 24 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3.5 | $1.12 | +212.50% | 1 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $21 | $13.30 | +57.89% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $6.17 | +256.56% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $77.32 | +29.33% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $169.56 | +146.52% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $14.93 | +87.54% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $12.49 | +436.43% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $9.55 | +810.99% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $2.79 | +796.06% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $24 | $10.07 | +138.33% | 1 | Oct 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $4.61 | +95.23% | 1 | Dec 12, 2016 |
LivaNova
Feb 27, 2026
Maintains: Equal-Weight
Price Target: $67 → $73
Current: $62.87
Upside: +16.11%
Alcon
Feb 26, 2026
Maintains: Equal-Weight
Price Target: $86 → $90
Current: $80.67
Upside: +11.57%
Globus Medical
Feb 25, 2026
Maintains: Overweight
Price Target: $118 → $123
Current: $86.17
Upside: +42.74%
Bausch + Lomb
Feb 19, 2026
Maintains: Equal-Weight
Price Target: $17 → $20
Current: $17.08
Upside: +17.10%
Medtronic
Feb 18, 2026
Maintains: Overweight
Price Target: $116 → $118
Current: $90.58
Upside: +30.27%
DexCom
Feb 13, 2026
Maintains: Underweight
Price Target: $71 → $72
Current: $68.18
Upside: +5.60%
Baxter International
Feb 13, 2026
Maintains: Overweight
Price Target: $30 → $25
Current: $17.78
Upside: +40.61%
Zimmer Biomet Holdings
Feb 12, 2026
Maintains: Underweight
Price Target: $104 → $100
Current: $92.56
Upside: +8.04%
Becton, Dickinson and Company
Feb 11, 2026
Reinstates: Overweight
Price Target: $202
Current: $165.46
Upside: +22.08%
GE HealthCare Technologies
Feb 6, 2026
Maintains: Equal-Weight
Price Target: $86 → $87
Current: $74.50
Upside: +16.78%
Feb 3, 2026
Maintains: Overweight
Price Target: $136 → $124
Current: $71.63
Upside: +73.11%
Feb 2, 2026
Maintains: Overweight
Price Target: $169 → $142
Current: $109.53
Upside: +29.64%
Jan 26, 2026
Maintains: Overweight
Price Target: $97 → $98
Current: $77.10
Upside: +27.11%
Jan 26, 2026
Maintains: Overweight
Price Target: $686 → $712
Current: $484.67
Upside: +46.90%
Jan 12, 2026
Maintains: Overweight
Price Target: $103 → $104
Current: $81.21
Upside: +28.06%
Jan 12, 2026
Downgrades: Underweight
Price Target: $316 → $274
Current: $235.92
Upside: +16.14%
Jan 9, 2026
Maintains: Overweight
Price Target: $11 → $12
Current: $4.46
Upside: +169.06%
Jan 7, 2026
Maintains: Overweight
Price Target: $23 → $27
Current: $12.20
Upside: +121.40%
Dec 30, 2025
Maintains: Equal-Weight
Price Target: $197 → $217
Current: $236.13
Upside: -8.10%
Nov 10, 2025
Maintains: Overweight
Price Target: $51 → $55
Current: $21.39
Upside: +157.13%
Nov 5, 2025
Maintains: Overweight
Price Target: $1.5 → $31
Current: $6.02
Upside: +414.95%
Oct 22, 2025
Maintains: Overweight
Price Target: $443 → $453
Current: $362.49
Upside: +24.97%
Aug 27, 2025
Initiates: Overweight
Price Target: $3.5
Current: $1.12
Upside: +212.50%
Jul 30, 2025
Maintains: Overweight
Price Target: $24 → $21
Current: $13.30
Upside: +57.89%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $6.17
Upside: +256.56%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $77.32
Upside: +29.33%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $169.56
Upside: +146.52%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $14.93
Upside: +87.54%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $12.49
Upside: +436.43%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $9.55
Upside: +810.99%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $2.79
Upside: +796.06%
Oct 10, 2017
Maintains: Buy
Price Target: $26 → $24
Current: $10.07
Upside: +138.33%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $4.61
Upside: +95.23%